Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group
- 4 February 2011
- journal article
- clinical trial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (1), 76-83
- https://doi.org/10.1002/pbc.22928
Abstract
Background The local control approach for girls with non‐resected vaginal rhabdomyosarcoma (RMS) enrolled onto Intergroup RMS Study Group (IRSG)/Children's Oncology Group (COG) studies has differed from that used at other primary sites by delaying or eliminating radiotherapy (RT) based on response achieved with chemotherapy and delayed primary resection. Procedures We reviewed locoregional treatment and outcome for patients with localized RMS of the vagina on the two most recent COG low‐risk RMS studies. Results Forty‐one patients with localized vaginal RMS were enrolled: 25 onto D9602 and 16 onto Subset 2 of ARST0331. Only four of the 39 with non‐resected tumors received RT. The 5‐year cumulative incidence of local recurrence was 26% on D9602, and the 2‐year cumulative incidence of local recurrence was 43% on ARST0331. Increased local failure rates appeared to correlate with chemotherapy regimens that incorporated lower cumulative doses of cyclophosphamide. Estimated 5‐year and 2‐year failure free survival rates were 70% (95% CI: 46%, 84%) on D9602 and 42% (95% CI: 11%, 70%) on ARST0331, respectively. Conclusions To prevent local recurrence, we recommend a local control approach for patients with non‐resected RMS of the vagina that is similar to that used for other primary sites and includes RT. We recognize that potential long‐term effects of RT are sometimes unacceptable, especially for children less than 24 months of age. However, when making the decision to eliminate RT, the risk of local recurrence must be considered especially when using a chemotherapy regimen with a total cumulative cyclophosphamide dose of ≤4.8 g/m2. Pediatr Blood Cancer 2011;57:76–83.Funding Information
- National Cancer Institute, Bethesda, Maryland (USA U10 CA98543, U10 CA98413)
This publication has 22 references indexed in Scilit:
- Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803Journal of Clinical Oncology, 2009
- Vulval and Vaginal Rhabdomyosarcoma in Children: Update and Reappraisal of Institut Gustave Roussy Brachytherapy ExperienceInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Late Effects of Pelvic Rhabdomyosarcoma and Its Treatment in Female SurvivorsJournal of Clinical Oncology, 2005
- Age Is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin, and CyclophosphamideJournal of Clinical Oncology, 2004
- Quality of life, self‐esteem and worries in young adult survivors of childhood cancerPsycho‐Oncology, 2004
- Quality of life in young adult survivors of childhood cancerSupportive Care in Cancer, 2002
- Rhabdomyosarcoma of the Urinary Bladder and VaginaThe American Journal of Surgical Pathology, 2001
- Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low‐dose etoposide on intergroup rhabdomyosarcoma study III: An interim reportMedical and Pediatric Oncology, 1994
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958